Iodixanol 550mg/ml (Iodine 270mg/ml) solution for injection 100ml bottles
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Iodixanol
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Iodixanol
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Iodixanol on the MHRA register
Visipaque 270 solution for injection 100ml bottles
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 1 · Randomised trials: 1 · 1996–2026
Showing the 50 most relevant studies, sorted by most relevant.
Naiju Zhang, Junran Gao, Zhenjie Wang, et al.
Frontiers in Cardiovascular Medicine, 2025
M.R. Sapoval, B.M. Beyssen, C. Girardot, et al.
Clinical Radiology, 1996
Winkelbauer M, Hasenauer A, Rütsche D, et al.
2025
- Collagen
- Tissue Engineering
- Bioprinting
Deep vat printing (DVP) techniques, including tomographic and filamented light (Flight) printing have transformed the tissue engineering landscape by enabling layer-free bioprinting at high resolution and speeds. Importantly, collagen is one of the most widely used materials in tissue biofabrication, but DVP using collagen-based photoresins has been under-explored. In this work, photoclickable collagen-based resins are demonstrated which are compatible with DVP, enabling prints with up to 50 µm print resolution and speeds less than 20 s per cm3. These resins contain iodixanol, which acts as a refractive index matching agent to reduce optical inhomogeneities by added cells and improves the stability of the collagen-based resins under neutralized conditions. As a potential application, multi-material tomographic and FLight printing is demonstrated to create intricate tissue constructs featuring muscle and connective tissue interfaces. While tomographic printing allows greater complexity over the overall shape of the constructs, FLight constructs demonstrate enhanced biomimicry through generation of aligned multinucleated myotubes, transition zones between the two cell types, and regularly spaced sarcomere structure (≈2.6 µm average sarcomere length) which facilitates contractility in the muscle regions. The demonstration of photoclickable, isotonic and neutral collagen-based bioresins offers a new solution for DVP of biomimetic complex tissues and grafts.
Abstract licence: CC BY
Shin YR, Youn SY, Kim H, et al.
2024
ObjectivesThis study aimed to analyze the usage patterns and hypersensitivity reaction (HSR) profiles of six nonionic iodinated contrast media (ICMs) used in computed tomography (CT) to enhance patient safety and inform evidence-based contrast agent selection.MethodsWe retrospectively reviewed 248,209 CT scans obtained between January 2020 and December 2022. Six ICMs (iomeprol, iohexol, ioversol, iopromide, iodixanol, and iobitridol) were compared on the basis of their usage rates, HSR incidence, and severity. This study also evaluated the impact of premedication protocol reinforcement and assessed the quarterly HSR rates.ResultsAmong the 248,209 CT scans, 1603 (0.65%) were associated with HSRs. Most HSRs were mild (86.2%), with moderate (10.9%) and severe (2.9%) reactions being less common. Four ICMs were used as first-line agents and two ICMs were used as second-line agents. The second-line agents, iobitridol and iodixanol, exhibited 7-8 times higher HSR rates compared to the first-line agents. A modified premedication protocol implemented in mid-2022 significantly reduced the incidence of moderate HSRs (p = 0.0075). The quarterly analysis indicated a trend in higher HSR rates in the first quarter and a statistically significant increase in severe HSRs in the third quarter (p = 0.033).ConclusionsThese findings highlight the importance of tailored premedication protocols and a 7-8 times higher rate of HSR with second-line agents in contrast-enhanced imaging. Future research should focus on elucidating the mechanisms underlying these variations to further refine contrast agent selection and management strategies.
Abstract licence: CC BY
Li Wang
2023
We are using the iodixanol gradient method to extract nuclei for 10X single cell and Multiome assays. We have tested this protocols with a range of primary brain samples, developing, postnatal and adult. We obtain clean nuclei, with least amount of ambient RNA. Using this protocol, we are able to remove most of the myelin from adolescent and adult samples, which generally interfere the nuclei counts before loading the 10X Controller. We have generated high quality GEX and ATAC-sequencing libraries with our samples from a range of ages, across different projects.
Abstract licence: CC BY 4.0
Paakkari P, Inkinen SI, Jäntti J, et al.
2025
- Cartilage, Articular
- Osteoarthritis
- Contrast Media
PurposePhoton-counting detectors (PCDs) are cutting-edge technology that enable spectral computed tomography (CT) imaging with a single scan. Spectral imaging is particularly effective in contrast-enhanced CT (CECT) imaging, especially when multiple contrast agents are utilized, as materials are distinguishable based on their unique X-ray absorption. One application of CECT is joint imaging, where it assesses the structure and composition of articular cartilage soft tissue. This evaluates articular cartilage and reveals compositional changes associated with early-stage osteoarthritis (OA) using a photon-counting detector CT (PCD-CT) technique combined with a dual-contrast agent method.MethodsA dual-contrast agent combination was used, consisting of proteoglycan-binding cationic tantalum oxide nanoparticles, developed in our lab, and a commercial non-ionic iodinated iodixanol agent. Ex vivo equine stifle joint cartilage samples (N = 30) were immersed in the contrast agent bath for 96 hours and imaged at multiple timepoints for analysis of proteoglycan, collagen, and water contents as well as collagen orientation, histological scoring, and biomechanical parameters.ResultsBy analyzing contrast agent concentrations, the technique provided a simultaneous assessment of the solid constituents and function of cartilage. Contrast agent diffusion depended on contrast agent composition and was significantly different between healthy and early-stage OA groups within 12 hours.ConclusionThe present study shows the promising utility of the dual-contrast PCD-CT technique for articular cartilage assessment and early-stage OA detection.
Abstract licence: CC BY
Jiang Y, Li S, Chen Z, et al.
2025
- Diabetes Mellitus
- Triiodobenzoic Acids
- Contrast Media
Ma X, He C, Zeng X, et al.
2025
- Triiodobenzoic Acids
- Contrast Media
- Acute Generalized Exanthematous Pustulosis
RationaleAcute generalized exanthematous pustulosis (AGEP) is a rare delayed allergic reaction, which is mostly caused by drugs, but there are few reports of iodixanol in particular. At present, 4 cases induced by iodixanol have been reported in the literature, but none have been reported in China.Patient concernsIn this report, we report a case of AGEP induced by intravenous bolus infusion of iodixanol during multislice spiral CT enhanced scanning of the whole abdomen in a patient with rectal malignancy. A 35-year-old female patient presented with a larger rash/erythema on the head and neck and felt itchy.DiagnosesA large erythema/rash and white, sterile pustules based on erythema spread from head, neck to the whole body in a short period of time. Blood cell results showed high levels of white blood cell, neutrophils, C-reactive protein and interleukin-10, and decreased levels of some immune indicators. Pathological biopsy results showed that there was immune cell infiltration around the superficial dermis.InterventionsImmediate avoidance of potential allergens and treatment with steroids, antihistamines and other medications, followed by adjustment with cyclosporine and human immunoglobulin.OutcomesAt 1 year's follow-up, the patient did not develop any symptoms of discomfort and increased awareness of allergen prevention.LessonsThe reported case is an extremely rare and severe AGEP, typically characterized by pruritus, edema, large erythema/rash, dense white needle-like sterile pustules based on erythema/rash, and desquamation. After discontinuation of exposure to iodixanol, the patient received symptomatic supportive treatment, mainly drug response. She eventually recovered without recurrence. In the future, with the in-depth exploration of more studies, the use of Iodine Contrast Media will be more standardized and scientific.
Abstract licence: CC BY
Liu K, Zuo R, Yu Y, et al.
2026
Tsurayya AH, Jäntti J, Paakkari P, et al.
2026
- Anterior Cruciate Ligament
- Posterior Cruciate Ligament
- X-Ray Microtomography
Detecting microstructural damage in ligaments remains a challenging case when no visible tearing occurs. This study introduces a novel application of micro-CT for ligament evaluation in wet tissue state with potential for clinical translation. We utilize neutral iodixanol and cationic tantalum oxide nanoparticles (Ta₂O₅-cNPs) for quantitative and qualitative imaging of microdamaged bovine ligaments. We hypothesize that neutral iodixanol reflects the ligament's functional alterations, while Ta₂O₅-cNPs will depict ligament structure by highlighting biphasic differences between the interfascicular matrix and fascicular regions. To examine these hypotheses, bovine anterior (N = 6) and posterior (N = 5) cruciate ligaments were assigned to control and damaged groups. All samples underwent biomechanical tensile testing to quantify the functional properties. Ligaments in the damaged group were strained up to 16% to create microdamage. Young's modulus was significantly reduced by 68% in the damaged group relative to the healthy group (p max of neutral iodixanol showed correlation with biomechanical properties specifically phase shift at frequencies of 0.1, 0.5, and 2 Hz indicating sensitivity to viscoelastic changes of the tissues, and (2) Ta₂O₅-cNPs enable visualization of the ligament's structures, supporting their potential for three-dimensional histological assessment.
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
2.1 hours
Mechanism
Organic iodine compounds attenuate x-rays as they pass through the body, thereby…
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Half-life
2.1 hours
Protein binding
Volume of distribution
0.26 L/kg
Metabolism
Elimination
97%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 733 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
ATC V08AB09
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Iodixanol
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72